Drs Sumanta Pal and Jose A. Karam, MD, discuss neoadjuvant therapy in renal cell carcinoma, including TKIs, immuno-oncology, and the need for more studies to explore the role of neoadjuvant therapy in RCC.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984249). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Renal Cell Carcinoma https://emedicine.medscape.com/article/281340-overview

Neoadjuvant Treatment in Renal Cell Carcinoma: Transforming Challenges Into Opportunities https://pubmed.ncbi.nlm.nih.gov/35248412/

Axitinib https://reference.medscape.com/drug/inlyta-axitinib-999715#10

Phase 2 Trial of Neoadjuvant Axitinib in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/24560330/

Renal Clear Cell Cancer https://www.ncbi.nlm.nih.gov/books/NBK563230/

Response Evaluation Criteria in Solid Tumors https://radiopaedia.org/articles/response-evaluation-criteria-in-solid-tumours?lang=us

Tyrosine Kinase Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK563322/

Tyrosine Kinase Inhibitors and Immunotherapy Combinations in Renal Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/32215057/

A Phase II Study of Pazopanib in Patients With Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma https://pubmed.ncbi.nlm.nih.gov/25813447/

Bevacizumab (Rx) https://reference.medscape.com/drug/avastin-mvasi-bevacizumab-342257

Everolimus (Rx) https://reference.medscape.com/drug/afinitor-zortress-everolimus-999101

Nivolumab (Rx) https://reference.medscape.com/drug/opdivo-nivolumab-999989

A Pilot Randomized Study Evaluating Nivolumab (Nivo) Or Nivo + Bevacizumab (Bev) Or Nivo + Ipilimumab (Ipi) in Patients With Metastatic Renal Cell Carcinoma (MRCC) Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy (Bx) https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4501

Ipilimumab (Rx) https://reference.medscape.com/drug/yervoy-ipilimumab-999636#10

TNM Classification https://www.ncbi.nlm.nih.gov/books/NBK553187/

A Phase II, Single-Arm Trial of Neoadjuvant Axitinib Plus Avelumab in Patients With Localized Renal Cell Carcinoma Who Are at High Risk of Relapse After Nephrectomy (NEOAVAX) https://pubmed.ncbi.nlm.nih.gov/31023100/

Inferior Venal Caval Thrombus https://emedicine.medscape.com/article/1933035-overview

A Phase II Study of Neoadjuvant Axitinib for Reducing the Extent of Venous Tumour Thrombus in Clear Cell Renal Cell Cancer With Venous Invasion (NAXIVA) https://pubmed.ncbi.nlm.nih.gov/35739300/

Surgical Management of Renal Cell Carcinoma With Associated Tumor Thrombus Extending Into the Inferior Vena Cava: A 10-Year Single-Center Experience https://pubmed.ncbi.nlm.nih.gov/30817278/